Please assess the completion status of the following clinical trial:

Trial Title: PGE1 as Additive Anticoagulant in ECMO-Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* minimum age 18 years~  * Veno-Venous- ECMO~ * Minimum of 24h planned ECMO- therapy~Exclusion Criteria:~* • Long- term therapy with other antiplatelet drugs including Acetyl Salicylic Acid~  * known Heparin induced thrombocytopenia~ * Bleeding diathesis = contraindication for heparin (e.g. GI-bleeding, Intracerebral bleeding)~ * Platelets \< 50 G/L~ * Thromboplastin time \< 50%~ * Pregnancy~ * Patient \< 18 years~ * prothrombin time \<50%~Drop out criteria:~* Major bleeding (from Type 3 bleeding; see primary objective)~* Occurrence of HIT (4 T- Score: Number of platelets, development over time, manifestation of thrombosis, other reasons for thrombocytopenia \[10\])~* Plt \< 50 G/l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alprostadil (Type: EXPERIMENTAL): heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
- Placebo (Type: PLACEBO_COMPARATOR): heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).